Literature DB >> 19263229

Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration.

Su-Bo Wang1, Yan-Na Cheng, Shu-Xiang Cui, Julia Li Zhong, S G Ward, Li-Rui Sun, Ming-Hui Chen, Norihiro Kokudo, Wei Tang, Xian-Jun Qu.   

Abstract

Des-gamma-carboxy prothrombin (DCP) is an aberrant prothrombin produced by hepatocellular carcinoma (HCC) cells. Serum and tissue DCP expressions are thought to reflect the biological malignant potential of HCC. However, the role of DCP in the development of angiogenesis is not well understood. Herein, we report the effects of DCP on growth and migration of human vascular endothelial cells. DCP significantly stimulated the proliferation of HUVEC (ECV304) cells in a dose and time dependent manner, as measured by the MTT assay. A continuous rapid migration of ECV304 cells was observed in the presence of DCP measured by the scratch wound assay. The continuous rapid invasive activity, measured by transwell chamber assay also showed that DCP increased endothelial cells migration through the reconstituted extracellular matrix (Matrigel). Further, the tube formation of vascular endothelial cells on 3-D Matrigel showed an increased number of branch points of ECV304 cells induced by DCP in a dose dependent manner. The levels of vascular endothelial cell growth-related angiogenic factors and matrix metalloproteinase were also examined. DCP significantly stimulated the expression levels of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and matrix metalloproteinase (MMP)-2 (latent and active). Together, these data suggest that DCP is a novel type of vascular endothelial growth factor that possesses potent mitogenic and migrative activities in angiogenesis of HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19263229     DOI: 10.1007/s10585-009-9246-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

1.  Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin.

Authors:  H A Liebman
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

2.  Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.

Authors:  Mayumi Suzuki; Hidenori Shiraha; Tatsuya Fujikawa; Nobuyuki Takaoka; Naoki Ueda; Yutaka Nakanishi; Kazuko Koike; Akinobu Takaki; Yasushi Shiratori
Journal:  J Biol Chem       Date:  2004-12-06       Impact factor: 5.157

Review 3.  Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors.

Authors:  L E Kemp; B Mulloy; E Gherardi
Journal:  Biochem Soc Trans       Date:  2006-06       Impact factor: 5.407

4.  Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration.

Authors:  Tatsuya Fujikawa; Hidenori Shiraha; Naoki Ueda; Nobuyuki Takaoka; Yutaka Nakanishi; Noriyuki Matsuo; Shigetomi Tanaka; Shin-ichi Nishina; Mayumi Suzuki; Akinobu Takaki; Kohsaku Sakaguchi; Yasushi Shiratori
Journal:  J Biol Chem       Date:  2007-01-25       Impact factor: 5.157

5.  A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score.

Authors:  Satoshi Kitai; Masatoshi Kudo; Yasunori Minami; Kazuomi Ueshima; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Emi Ishikawa; Shunsuke Takahashi; Yutaka Asakuma; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Intervirology       Date:  2008-06-10       Impact factor: 1.763

6.  gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin.

Authors:  Toru Naraki; Noriatsu Kohno; Hiroyuki Saito; Yoshinori Fujimoto; Motoyuki Ohhira; Takashi Morita; Yutaka Kohgo
Journal:  Biochim Biophys Acta       Date:  2002-04-24

7.  The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.

Authors:  Ken Shirabe; Shinji Itoh; Tomoharu Yoshizumi; Yuji Soejima; Akinobu Taketomi; Shin-Ichi Aishima; Yoshihiko Maehara
Journal:  J Surg Oncol       Date:  2007-03-01       Impact factor: 3.454

8.  Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation.

Authors:  Pooja Dua; Rajiv P Gude
Journal:  Eur J Cancer       Date:  2008-05-19       Impact factor: 9.162

9.  Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells.

Authors:  Fu-Jun Gao; Shu-Xiang Cui; Ming-Hui Chen; Yan-Na Cheng; Li-Rui Sun; S G Ward; Norihiro Kokudo; Wei Tang; Xian-Jun Qu
Journal:  Life Sci       Date:  2008-10-21       Impact factor: 5.037

10.  Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil.

Authors:  Jian Liu; Xun Li; Yan-na Cheng; Shu-xiang Cui; Ming-hui Chen; Wen-fang Xu; Zhi-gang Tian; Masatoshi Makuuchi; Wei Tang; Xian-jun Qu
Journal:  Eur J Pharmacol       Date:  2007-08-07       Impact factor: 4.432

View more
  15 in total

1.  Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection.

Authors:  Rumi Matono; Shohei Yoshiya; Takashi Motomura; Takeo Toshima; Hiroto Kayashima; Toshiro Masuda; Tomoharu Yoshizumi; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara
Journal:  HPB (Oxford)       Date:  2012-02-03       Impact factor: 3.647

Review 2.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

Review 3.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin.

Authors:  Jian-Jun Gao; Zu-Hua Gao; Cui-Rong Zhao; Yi Yuan; Shu-Xiang Cui; Xiao-Fan Zhang; Yan-Na Cheng; Wen-Fang Xu; Wei Tang; Xian-Jun Qu
Journal:  Invest New Drugs       Date:  2010-01-29       Impact factor: 3.850

5.  2K1C-activated Angiotensin II (Ang II) exacerbates vascular damage in a rat model of arthritis through the ATR/ERK1/2 signaling pathway.

Authors:  Ying Zhang; Xuexia Luo; Yue Zhou; Huaxun Wu; Jingyu Chen; Ying Wang; Danian Chen; Zhouwei Xu; Shangxue Yan; Wei Wei
Journal:  Inflamm Res       Date:  2017-06-26       Impact factor: 4.575

6.  Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.

Authors:  Shu-Xiang Cui; Wen-Na Shi; Zhi-Yu Song; Shu-Qing Wang; Xin-Feng Yu; Zu-Hua Gao; Xian-Jun Qu
Journal:  Oncotarget       Date:  2016-06-14

7.  Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma.

Authors:  Yoshimichi Haruna; Noriko Hasegawa; Kazuho Imanaka; Seiichi Kawamoto; Atsuo Inoue
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

8.  Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.

Authors:  Jun Ji; Hao Wang; Yan Li; Lei Zheng; Yuepeng Yin; Zhenzhen Zou; Feiguo Zhou; Weiping Zhou; Feng Shen; Chunfang Gao
Journal:  PLoS One       Date:  2016-04-12       Impact factor: 3.240

9.  Morusin shows potent antitumor activity for human hepatocellular carcinoma in vitro and in vivo through apoptosis induction and angiogenesis inhibition.

Authors:  Ling Gao; Li Wang; Zhen Sun; Haiyan Li; Qiaoping Wang; Cheng Yi; Xiujie Wang
Journal:  Drug Des Devel Ther       Date:  2017-06-16       Impact factor: 4.162

Review 10.  Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Maria J Citores; Jose L Lucena; Sara de la Fuente; Valentin Cuervas-Mons
Journal:  World J Hepatol       Date:  2019-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.